|
|
|
IAS Satellite Session – July 20, 2015
Mucosal Immunology Research in Canada: Collaborative Contributions to the Field
Join us for a special satellite session at IAS 2015 on “Mucosal Immunology Research in Canada: Collaborative Contributions to the Field”. Mucosal immunology of the reproductive tract is a critical area of investigation for HIV vaccines, and this satellite aims to highlight the contribution of three of Canada’s leading teams working in this area. Presenters include Charles Wira (Dartmouth Medical School), Rupert Kaul (University of Toronto), Charu Kaushic (McMaster University), and Adam Burgener (National HIV and Retrovirology Laboratories/University of Manitoba). They will discuss important research gaps, such as the early events in the genital tract during sexual transmission, how immune processes in the female genital tract lead to HIV acquisition; and how changes in a woman’s hormones, genital microflora and immune system increase risk of HIV infection. Spaces are limited so registration is required. To register send an email to aco@icid.com by July 15, 2015. For more information email aco-projects@icid.com.
When: Monday, July 20, 2015
Time: 7:00 to 8:30 a.m.
Location: Room 110, Vancouver Convention Centre, Vancouver, British Columbia
Continental breakfast will be served
|
| |
|
Want to Know What the ACO has Been Up To?
Featured Videos: CAHR 2015 Vaccine Scholars
The ACO was pleased to partner with the Canadian Association for HIV Research (CAHR) to offer eight academic scholarships in vaccine research at the CAHR 2015 Conference. The scholarships are awarded based purely on scientific merit. The following two award recipients presented their research at the conference:
|
Angela Harris is a master’s student at the University of Manitoba whose research team hypothesizes that if interferon regulatory factor (IRF)-1 or IRF-7 expression is knocked down, cells will have lowered antiviral responses and be more susceptible to HIV infection. WATCH THE VIDEO
|
|
Vanessa Wacleche is a new investigator at Centre de recherche du CHUM who presented her research about discovering two new subsets of Th17 cells and their impact on HIV. WATCH THE VIDEO
|
New Research
|
|
|
|
Characterization and Implementation of a Diverse SIVsm Envelope Panel in the Assessment of Neutralizing Antibody Breadth Elicited in Rhesus Macaques by Multi-Modal Vaccines Expressing the SIVmac239 Envelope
Kilgore KM, Murphy MK, Burton SL, et al.
J Virol. 2015 May 27. pii: JVI.01221-14. [Epub ahead of print]
Using a novel SIV neutralization panel and samples from four rhesus macaque vaccine trials designed for cross-comparison, we show that different regimens expressing the same SIV envelope immunogen consistently elicit antibodies that neutralize only the very sensitive tier 1a SIV variants. The results argue that the neutralizing antibody profile elicited by a vaccine is primarily determined by the envelope immunogen and is not substantially broadened by including adjuvants, resulting in the conclusion that the envelope immunogen itself should be the primary consideration in efforts to elicit antibodies with greater neutralization breadth. READ MORE.
PQBP1 protein could improve body's immune response to HIV vaccines
News Medical, June 5, 2015
Dhalla S, Poole G
In a scientific discovery that has significant implications for preventing HIV infections, researchers at Sanford-Burnham Medical Research Institute (Sanford-Burnham) have identified a protein that could improve the body's immune response to HIV vaccines and prevent transmission of the virus READ MORE.
Resources
Canadian HIV Vaccine Initiative (CHVI) Interactive Projects Map
The CHVI's Interactive Projects Map highlights recipients of CHVI funding around the world and visual guide to some of Canada's contribution to HIV/AIDS research. TRY THE MAP to find out where Canadian HIV vaccine research is taking place.
|
|
Conferences
|
|
July 19 to 22, 2015
IAS 2015
8th International AIDS Society Conference on HIV Pathogenesis, Treatment & Prevention
Vancouver, Canada
Stop by the ACO booth in the exhibit hall!
|
|
September 13 to 16, 2015
World STI & HIV 2015 Congress
Brisbane, Australia
|
|
November 30 to December 2, 2015
3rd International Conference on HIV/AIDS, STDs & STIs
Atlanta, USA
|
|
May 12 to 15, 2016
CAHR 2016
Winnipeg, Canada
|
|
May 23 to 24, 2016
ICHA 2016 (International Conference on HIV and AIDS)
London, United Kingdom
|
|
July 17 to 22, 2016
AIDS 2016
Durban, South Africa
|
|
→
See full list of conferences
|
|
| |
| |
| |
| |
|
You are receiving this email because you registered to receive news updates from the Canadian HIV Vaccine Initiative (CHVI) Research and
Development Alliance Coordinating Office
or you are a member of a CHVI-funded
project team.
|
| |
|
Follow Us:
|
|
|
| |
| |
|
Address
|
|
ALLIANCE COORDINATING OFFICE
International Centre for Infectious Diseases
515 Portage Avenue
Winnipeg, MB, Canada
R3B 2E9
Tel.: 204 946 0908
Fax: 204 946 0927
email:
aco@icid.com
|
|
| |
| |
|
About Us
|
|
The CHVI Research and Development Alliance Coordinating Office (ACO) was established by the Government of Canada and the Bill & Melinda Gates Foundation in November 2011 at the International Centre for Infectious Diseases (ICID), a
not-for-profit,
non-governmental organization based in Winnipeg.
|
|
| |
|
White Paper
|
The ACO has developed a White Paper to foster effective coordination of key players across the Canadian HIV vaccine research landscape.
|
|
Read more
|
|
|
